Slide 1: Business Update and Full Year and Q4 2021 Financial Results
Business Update and Full Year and Q4 2021 Financial Results NASDAQ: OCGN 1
Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation contains forward‐looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “c
Slide 3: TRATEGY
TRATEGY RISE i= ~ = ° h_ u) PROCESS f ADVANCEMENT MODIFY Transformation = (Bioeng B 2 stateaes § CHANGE ME Change prove OY ivncverion 0) emai = Reorganization seune’ Development Build ALTERAT
Slide 4: Forward Momentum for COVAXIN (BBV152)
Forward Momentum for COVAXIN™ (BBV152) 4 02 • Comprehensive responses submitted to Health Canada against notice of deficiency • Letter‐of‐Intent signed with Liminal BioSciences for acquisition of new Canada‐ based manufacturing facility; • Tech transfer progressing with partner, JHS • U.S. FDA lifts
Slide 5: Forward Momentum for Ocular Portfolio
Forward Momentum for Ocular Portfolio 5 • Phase 1/2 clinical trials studying OCU400 for the treatment of retinitis pigmentosa resulting from genetic mutations of NR2E3 and RHO now enrolling • Currently executing IND‐enabling preclinical studies to support a Phase 1/2a clinical trial OCU200 OCU40001
Slide 6: Financial Update
FINANCIAL UPDATE © ocugen. es
Slide 7: Financial Update: Statement of Operations and Balance Sheet Data
Financial Update Statement of Operations Three months ended December 31, Year ended December 31, 2021 2020 2021 2020 Research and development expense $7.1 $1.6 $35.1 $6.4 In‐process research and development expense — — — 7.0 General and administrative expense 7.5 2.2 22.9 8.0 Other income (expense),
Slide 8: Q&A
8 Q&A
Slide 9: Business Update and Full Year and Q4 2021 Financial Results
NASDAQ: OCGN 9 Business Update and Full Year and Q4 2021 Financial Results